News

Member Feature – Penn Medicine

Founded in 1765 as the nation’s first medical school, Penn Medicine, consisting of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania, and the University of Pennsylvania Health System, together form a $8.6 billion enterprise. The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to US News & World Report’s survey of research-oriented medical schools. The School is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $494 million awarded in the 2019 fiscal year. Penn Medicine has been actively involved with our Chapter since entering the UK market. We are lucky to have one of the world’s leading academic medical centers in our region. Penn Medicine is dedicated to medical education, biomedical research, and excellence in patient care. More than ever before, universities, research institutes, pharma, biotechs and start-ups are collaborating to develop a vaccine and treatments for Covid-19. Penn Medicine has developed active clinical trials for patients with COVID 19, a plasma donation protocol for those that have recovered from COVID-19, and a vaccine trial for health volunteers. They are also working together throughout different University-wide disciplines to assemble teams to address emergent unmet needs. Penn is leading the US component for the pathbreaking intubateCOVID Global Registry, which tracks global patterns in airway management activity and personal protective equipment (PPE) use to help inform COVID-19 care and health policies in the United States and beyond. intubateCOVID will use previously identified global patterns to quantify the personal risk of COVID-19 disease development in US providers. The Group was first established in the United Kingdom to track exposures and outcomes among providers who perform intubations in confirmed or suspected COVID-19. The registry is entirely voluntary. In consultation with leadership of the Perelman School of Medicine, the Microbiology Department founded the Center for Research on Coronavirus and Other Emerging Pathogens. The goals of the Center are to:
• Expand and accelerate SARS-CoV-2 research at Penn, CHOP and Wistar.
• Provide centralized information on SARS-CoV-2 research developments in our community and globally.
• Compile information and catalyze opportunities for new funding for research on SARS-CoV-2 and other emerging pathogens.

The BABCPHL is proud to feature member Penn Medicine in this weekly news update, and to highlight some of the many examples of the worldwide collaborative effort to respond to the global health crisis. We’d like to express our gratitude to all of the healthcare workers, scientists, and researchers throughout the world for the steadfast care and groundbreaking work to ensure health and safety.

Leave a Reply

↑ back to top


The BABCPHL recognizes our Club Level Members:

  • Almac
  • American Airlines
  • Cigna
  • Cigna
  • Deloitte
  • Duane Morris
  • EisnerAmper LLP
  • Faegre Drinker Biddle & Reath LLP
  • Fisher Phillips
  • HSBC
  • International Products Corporation
  • Johnson, Kendall & Johnson, Inc.
  • KPMG
  • Morgan Lewis
  • Virgin Atlantic
  • Welsh Government